东阿阿胶半年营收超30亿增11% 拟派现8.17亿分红率达99.94%

Core Insights - Dong'e Ejiao reported strong financial performance for the first half of 2025, with revenue of 3.051 billion yuan, a year-on-year increase of 11.02%, and a net profit of 818 million yuan, up 10.74% [1][2] Financial Performance - The company's core product, Ejiao and its series, generated revenue of 2.845 billion yuan, reflecting a growth of 11.50% and accounting for over 90% of total revenue [1][2] - The net profit excluding non-recurring items reached 788 million yuan, marking a 12.58% increase [2] - As of the end of June 2025, the company's debt-to-asset ratio was only 19.17%, indicating very low solvency risk [2] Brand and Market Position - Dong'e Ejiao maintained a market share of 67.3% in the Ejiao block category, reinforcing its leadership in the OTC market [2] - The brand's value increased to 49.697 billion yuan, with a ranking improvement to 245th in the "China's 500 Most Valuable Brands" list [2] Research and Development - The company invested 114 million yuan in R&D during the first half of 2025, a 48.02% increase year-on-year, focusing on five key areas including traditional Chinese medicine and health consumer products [2] Dividend Policy - Dong'e Ejiao proposed a cash dividend of 8.17 billion yuan, which represents 99.94% of the net profit attributable to shareholders for the first half of 2025 [3] - The total dividend distributed over the years has surpassed 10.104 billion yuan, with an average payout ratio of nearly 70% since the first dividend in 1999 [3]